ABCC8 polymorphism (Ser1369Ala): Influence on severe hypoglycemia due to sulfonylureas

Pharmacogenomics

Volumn 11, Issue 12, 2010, Pages 1743-1750

  Sato, Ryosuke ^a,b   Watanabe, Hiroshi ^a   Genma, Rieko ^b   Takeuchi, Masahiro ^c   Maekawa, Masato ^a   Nakamura, Hirotoshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SEIREI HAMAMATSU GENERAL HOSPITAL   (Japan)

^c KITASATO UNIVERSITY   (Japan)

Author keywords

ABCC8; diabetes mellitus; hypoglycemia; KATP channel; polymorphism; Ser1369Ala; sulfonylurea

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C8; ADENOSINE TRIPHOSPHATE; ALANINE; ALPHA GLUCOSIDASE INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; INSULIN; METFORMIN; PIOGLITAZONE; POTASSIUM CHANNEL; SERINE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

AGED; ALLELE; ARTICLE; BINDING SITE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; STRUCTURE ACTIVITY RELATION;

AGED; ATP-BINDING CASSETTE TRANSPORTERS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DNA; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LEUKOCYTES; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, DRUG; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK; SEVERITY OF ILLNESS INDEX; SULFONYLUREA COMPOUNDS;

EID: 78650321826     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.135     Document Type: Article

References (27)

1. Zammitt NN, Frier BM: Hypoglycemia in Type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 28, 2948-2961 (2005).
2. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP, Selby JV: Hypoglycemic episodes and risk of dementia in older patients with Type 2 diabetes mellitus. JAMA 301, 1565-1572 (2009).
3. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V: Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 26, 1485-1489 (2003).
4. Pearson ER, Donnelly LA, Kimber C et al.: Variation in TCF7L2 infuences therapeutic response to sulfonylureas - a GoDARTs study. Diabetes 56, 2178-2182 (2007).
5. Becker ML, Visser, LE, Trienekens, PH, Hofman, A, van Schaik R, Stricker B: Cytochrome P450 2C9*2 and *3 polymorphisms and the dose and effect of sulfonylurea in Type II diabetes mellitus. Clin. Pharmacol. Ther. 83, 288-292 (2008).
6. Sattiraju S, Reyes S, Kane GC, Terzic A: K-ATP channel pharmacogenomics: from bench to bedside. Clin. Pharmacol. Ther. 83, 354-357 (2008).
7. Aittoniemi J, Fotinou C, Craig TJ, De Wet H, Proks P, Ashcroft FM: SUR1: a unique ATP-binding cassette protein that functions as an ion channel regulator. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 364, 257-267 (2009).
8. Vila-Carriles WH, Zhao GL, Bryan J: Defning a binding pocket for sulfonylureas in ATP-sensitive potassium channels. FASEB J. 21, 18-25 (2007).
9. Winkler M, Stephan D, Bieger S, Kuhner P, Wolff F, Quast U: Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A+B-site ligands. J. Pharmacol. Exp. Ther. 322, 701-708 (2007).
10. + channel. Diabetes 58, 2419-2424 (2009).
11. Feng Y, Mao G, Ren X et al.: Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic effcacy of gliclazide in Chinese Type 2 diabetic patients. Diabetes Care 31, 1939-1944 (2008).
12. Hansen T, Echwald SM, Hansen L et al.: Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affnity sulfonylurea receptor gene. Diabetes 47, 598-605 (1998).
13. Ohta Y, Tanizawa Y, Inoue H et al.: Identifcation and functional analysis of sulfonylurea receptor 1 variants in Japanese patients with NIDDM. Diabetes 47, 476-481 (1998).
14. Babenko AP, Polak M, Cave H et al.: Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N. Engl. J. Med. 355, 456-466 (2006).
15. Rafq M, Flanagan SE, Patch AM et al.: Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care 31, 204-209 (2008).
16. Thomas PM, Cote GJ, Wohllk N et al.: Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 268, 426-429 (1995)
17. Laukkanen O, Pihlajamaki J, Lindstrom J et al.: Polymorphisms of the SUR1 (ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to Type 2 diabetes. The Finnish diabetes Prevention Study. J Clin Endocrinol Metab 89, 6286-6290 (2004). (Pubitemid 39628447)
18. Yokoi N, Kanamori M, Horikawa Y et al.: Association studies of variants in the genes involved in pancreatic p-cell function in Type 2 diabetes in Japanese subjects. Diabetes 55, 2379-2386 (2006).
19. Florez JC, Jablonski KA, Kahn SE et al.: Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S infuence progression to diabetes and response to interventions in the diabetes prevention program. Diabetes 56, 531-536 (2007).
20. Xu HM, Murray M, McLachlan AJ: Infuence of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of sulfonylurea drugs. Curr. Drug Metab. 10, 643-658 (2009).
21. Rissanen J, Markkanen A, Karkkainen P et al.: Sulfonylurea receptor 1 gene variants are associated with gestational diabetes and Type 2 diabetes but not with altered secretion of insulin. Diabetes Care 23, 70-73 (2000).
22. Gloyn AL, Pearson ER, Antcliff JF et al.: Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med. 350, 1838-1849 (2004).
23. Thomas P, Ye Y, Lightner E: Mutation of the pancreatic islet inward rectifer Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum. Mol. Genet. 5, 1809-1812 (1996).
24. Holstein A, Hahn M, Stumvoll M, Kovacs P: The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with Type 2 diabetes. Horm. Metab. Res. 41, 387-390 (2009).
25. Holstein A, Plaschke A, Ptak M et al.: Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br. J. Clin. Pharmacol. 60, 103-106 (2005).
26. Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG: Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 10, 1781-1787 (2009).
27. Nasu K, Kubota T, Ishizaki T: Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 7, 405-409 (1997).